
## Catherine R Rowan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3546428/publications.pdf

Version: 2024-02-01



CATHERINE R ROWAN

#	Article	IF	CITATIONS
1	An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis. Expert Opinion on Pharmacotherapy, 2022, 23, 893-904.	1.8	3
2	Visceral adiposity and inflammatory bowel disease. International Journal of Colorectal Disease, 2021, 36, 2305-2319.	2.2	24
3	Mucosal inflammation downregulates PHD1 expression promoting a barrierâ€protective HIFâ€1α response in ulcerative colitis patients. FASEB Journal, 2020, 34, 3732-3742.	0.5	16
4	Hypoxia-inducible factor hydroxylase inhibition enhances the protective effects of cyclosporine in colitis. American Journal of Physiology - Renal Physiology, 2019, 317, G90-G97.	3.4	10
5	Acceptance and Commitment Therapy Reduces Psychological Stress in Patients With Inflammatory Bowel Diseases. Gastroenterology, 2019, 156, 935-945.e1.	1.3	114
6	Ustekinumab Drug Levels in Maternal and Cord Blood in a Woman With Crohn's Disease Treated Until 33 Weeks of Gestation. Journal of Crohn's and Colitis, 2018, 12, 376-378.	1.3	50
7	Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study. Alimentary Pharmacology and Therapeutics, 2018, 48, 333-339.	3.7	14
8	Severe Symptomatic Primary CMV Infection in Inflammatory Bowel Disease Patients with Low Population Seroprevalence. Gastroenterology Research and Practice, 2018, 2018, 1-5.	1.5	12
9	Multifocal Motor Neuropathy Associated with Infliximab. Journal of Crohn's and Colitis, 2015, 9, 1174-1175.	1.3	7